Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
ESTRACE |
| Manufacturer |
|
Warner Chilcott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol 0.5mg, 1mg, 2mg+; scored tabs; +contains tartrazine. |
| Indications |
|
Palliative treatment of androgen-dependent advanced prostate cancer. Palliative treatment of metastatic breast cancer in select patients (see literature). |
| Children |
|
Not applicable. |
| Adults |
|
Prostate cancer: 1–2mg 3 times daily. Breast cancer: 10mg 3 times daily for at least 3 months. |
| Contraindications |
|
Thrombophlebitis. Thromboembolic disorders. Cerebrovascular disorders. Abnormal undiagnosed genital bleeding. Estrogen-depended neoplasias. Liver dysfunction or disease. Pregnancy (Cat. X). |
| Precautions |
|
Asthma (2mg tabs). Hepatic dysfunction. Conditions aggravated by fluid retention. Cardiovascular disorders, arterial vascular disease, and risks factors (eg, hypertension, diabetes, obesity, SLE). Familial hyperlipoprotenemia. Monitor BP. Discontinue if jaundice occurs and before prolonged immobilization (eg, surgery). Nursing mothers. |
| Adverse Reactions |
|
See literature. GI upset, headache, hypertension, edema, hypercalcemia, gallbladder or thromboembolic disease, gynecomastia, impotence, impaired glucose tolerance. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
